Get the Stockscreener App
0.00
100.00%
-3.37
After Hours:
3.38
3.38
+
Acasti Pharma Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.
See More
Previous Close:
$3.37
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$34.17M
Revenue:
-
Net Income/Loss:
$-38.77M
P/E Ratio:
0.00
EPS:
-5.64
Net Cash Flow:
$-13.57M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$3.60
Acasti Pharma Inc Stock (ACST) Company Profile
Name
Acasti Pharma Inc
Sector
Industry
Phone
609-649-9272
Address
103 CARNEGIE CENTER, PRINCETON, QC
Compare ACST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACST
Acasti Pharma Inc
|
0.00 | 34.17M | 0 | -38.77M | -13.57M | -4.5778 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Acasti Pharma Inc Stock (ACST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-20 | Upgrade | B. Riley FBR | Neutral → Buy |
| Jan-13-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-29-19 | Initiated | B. Riley FBR | Buy |
| Jul-18-19 | Initiated | Oppenheimer | Outperform |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Acasti Pharma Inc Stock (ACST) Latest News
Acasti and CordenPharma look to continuous production for omega-3 drug - OutSourcing-Pharma.com
Acasti Pharma stock soars to 52-week high of $3.61 By Investing.com - Investing.com Canada
Acasti Pharma stock soars to 52-week high of $3.61 - Investing.com
Acasti Pharma (CVE:ACST) Stock Price Up 1.8% – What’s Next? - Defense World
Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023 - Quantisnow
Financial Contrast: Annexon (NASDAQ:ANNX) & Acasti Pharma (NASDAQ:ACST) - Defense World
Block Inc (SQ-N) QuotePress Release - The Globe and Mail
Acasti Pharma Inc. Announces Poster Detailing Its GTX-104 STRIVE-ON Trial - Marketscreener.com
OTC Markets Hosts Virtual Investor Presentation with Prashant Kohli, CEO of Grace Therapeutics (Acasti Pharma), with John Vandermosten, Senior Analyst at Zacks SCR - MSN
Acasti Pharma Inc. Announces Resignation of Jean-Marie Canan from Board of Directors and Member of Audit Committee and Governance and Human Resources Committee - Marketscreener.com
Acasti Pharma Insider Bought Shares Worth $1,249,934, According to a Recent SEC Filing - Marketscreener.com
Grace Therapeutics announces name change and new ticker - Investing.com India
Reviewing Immunic (NASDAQ:IMUX) & Acasti Pharma (NASDAQ:ACST) - Defense World
Acasti Pharma transitions to Grace Therapeutics, trading as GRCE - Investing.com India
ACSTAcasti Pharma, Inc. Latest Stock News & Market Updates - StockTitan
Acasti Pharma Changes Name to Grace Therapeutics - Marketscreener.com
Acasti Pharma transitions to Grace Therapeutics, trading as GRCE By Investing.com - Investing.com UK
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. - GlobeNewswire
Acasti Pharma stock soars to 52-week high of $3.6 amid bullish run - Investing.com
Acasti Pharma (FRA:L8S) Debt-to-EBITDA : 0.00 (As of Jun. 2024) - GuruFocus.com
Acasti Pharma (NASDAQ:ACST) Stock Crosses Above 200 Day Moving Average – Here’s What Happened - Defense World
Aneurysmal Subarachnoid Hemorrhage Market Expected - openPR
Acasti Pharma announces key corporate changes and new incentive plan By Investing.com - Investing.com Canada
Acasti Pharma announces key corporate changes and new incentive plan - Investing.com
Acasti Pharma shares gain analyst confidence, price target raised based on GTX-104 potential - Investing.com Canada
Acasti Pharma shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com Canada
Investment Analysts’ Price Target Changes for September 26th (ACST, AFL, ALLY, AVAP, BK, BLKB, CCI, CHRW, CNXC, CROX) - Defense World
Acasti Pharma (ACST) Stock Surges Following Major Clinical Trial Milestone - Stocks Telegraph
Astera Labs director Jack Lazar sells over $1.2m in stock - Investing.com India
Comparing ARS Pharmaceuticals (NASDAQ:SPRY) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Astria Therapeutics (NASDAQ:ATXS) Shares Gap Down to $12.50 - MarketBeat
A year in review: Astria Therapeutics Inc (ATXS)’s performance in the last year - US Post News
Deeper Dive: Understanding Astera Labs Inc. (ALAB) Through its Various Ratios - The Dwinnex
Acadia Pharmaceuticals Inc (ACAD) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Acasti Pharma Inc. Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104 - Marketscreener.com
Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104 - GlobeNewswire
Casey’s General Stores, Inc. (NASDAQ:CASY) Shares Sold by Public Employees Retirement Association of Colorado - Defense World
Victory Capital Management Inc. Has $88,000 Position in Acacia Research Co. (NASDAQ:ACTG) - Defense World
Aterian Plc Expands Share Capital and Grants Warrants - TipRanks
Actinium Pharmaceuticals (ATNM) vs. Its Rivals Head to Head Comparison - Defense World
asti stock touches 52-week low at $2.32 amid steep annual decline - Investing.com India
Sagefield Capital LP Invests $1.64 Million in Atlantica Sustainable Infrastructure plc (NASDAQ:AY) - Defense World
1832 Asset Management L.P. Cuts Holdings in Casey’s General Stores, Inc. (NASDAQ:CASY) - Defense World
Acadia Pharmaceuticals appoints Catherine Owen Adams CEO, shares fall - XM
Magnetar Financial LLC Buys Shares of 20,305 Astera Labs, Inc. (NASDAQ:ALAB) - Defense World
Views of Wall Street’s Leading Experts on Astera Labs Inc. - SETE News
Acadia Pharmaceuticals Inc (ACAD) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Skandinaviska Enskilda Banken AB publ Acquires 900 Shares of Acuity Brands, Inc. (NYSE:AYI) - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Sold by Logos Global Management LP - MarketBeat
Long Term Trading Analysis for (ATXS) - Stock Traders Daily
Casey's General Stores, Inc. (NASDAQ:CASY) Position Lifted by Samlyn Capital LLC - MarketBeat
Acasti Pharma Inc Stock (ACST) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):